BridgeBio Pharma, Inc. Interest Expense, Debt, Excluding Amortization
BridgeBio Pharma, Inc. (BBIO) reported Interest Expense, Debt, Excluding Amortization of $10.16 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebtExcludingAmortization · last filed 2025-08-05
- BridgeBio Pharma, Inc. interest expense, debt, excluding amortization for the quarter ending 2025-06-30 was $10.16M, a 32.91% increase year-over-year.
- BridgeBio Pharma, Inc. interest expense, debt, excluding amortization for the quarter ending 2025-03-31 was $8.48M, a 10.98% increase year-over-year.
- BridgeBio Pharma, Inc. interest expense, debt, excluding amortization for the quarter ending 2024-12-31 was $7.64M, a 0.00% change year-over-year.
- BridgeBio Pharma, Inc. interest expense, debt, excluding amortization for the quarter ending 2024-09-30 was $7.64M, a 0.00% change year-over-year.
- BridgeBio Pharma, Inc. interest expense, debt, excluding amortization for fiscal 2024 was $30.57M, a 0.00% change from fiscal 2023.
- BridgeBio Pharma, Inc. interest expense, debt, excluding amortization for fiscal 2023 was $30.57M, a 0.00% change from fiscal 2022.
- BridgeBio Pharma, Inc. interest expense, debt, excluding amortization for fiscal 2022 was $30.57M, a 4.31% increase from fiscal 2021.
- BridgeBio Pharma, Inc. interest expense, debt, excluding amortization for fiscal 2021 was $29.31M.
| Period end | Interest Expense, Debt, Excluding Amortization 3 month | Interest Expense, Debt, Excluding Amortization 4 month | Interest Expense, Debt, Excluding Amortization 6 month | Interest Expense, Debt, Excluding Amortization 7 month | Interest Expense, Debt, Excluding Amortization 9 month | Interest Expense, Debt, Excluding Amortization 12 month |
|---|---|---|---|---|---|---|
| 2025-06-30 | $10.16M 10-Q · filed 2025-08-05 | $18.64M 10-Q · filed 2025-08-05 | $26.28M derived: sum of 3 quarters · filed 2025-08-05 | $33.92M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2025-03-31 | $8.48M 10-Q · filed 2025-04-29 | $16.12M derived: sum of 2 quarters · filed 2025-04-29 | $23.77M derived: sum of 3 quarters · filed 2025-04-29 | $31.41M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-12-31 | $7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $15.29M derived: sum of 2 quarters · filed 2025-02-20 | $22.93M derived: sum of 3 quarters · filed 2025-08-05 | $30.57M 10-K · filed 2025-02-20 | ||
| 2024-09-30 | $7.64M 10-Q · filed 2024-11-12 | $15.28M derived: sum of 2 quarters · filed 2025-08-05 | $22.93M 10-Q · filed 2024-11-12 | $30.57M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-06-30 | $7.64M 10-Q · filed 2025-08-05 | $15.28M 10-Q · filed 2025-08-05 | $22.93M derived: sum of 3 quarters · filed 2025-08-05 | $30.57M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $7.64M 10-Q · filed 2025-04-29 | $15.29M derived: sum of 2 quarters · filed 2025-04-29 | $22.93M derived: sum of 3 quarters · filed 2025-04-29 | $30.57M derived: sum of 4 quarters · filed 2025-04-29 | ||
| 2023-12-31 | $7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $15.29M derived: sum of 2 quarters · filed 2025-02-20 | $22.93M derived: sum of 3 quarters · filed 2025-02-20 | $30.57M 10-K · filed 2025-02-20 | ||
| 2023-09-30 | $7.64M 10-Q · filed 2024-11-12 | $15.28M derived: sum of 2 quarters · filed 2024-11-12 | $22.93M 10-Q · filed 2024-11-12 | $30.57M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-06-30 | $7.64M 10-Q · filed 2024-08-01 | $15.28M 10-Q · filed 2024-08-01 | $22.93M derived: sum of 3 quarters · filed 2025-02-20 | $30.57M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2023-03-31 | $7.64M 10-Q · filed 2024-05-02 | $15.29M derived: sum of 2 quarters · filed 2025-02-20 | $22.93M derived: sum of 3 quarters · filed 2025-02-20 | $30.57M derived: sum of 4 quarters · filed 2025-02-20 | ||
| 2022-12-31 | $7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $15.29M derived: sum of 2 quarters · filed 2025-02-20 | $22.93M derived: sum of 3 quarters · filed 2025-02-20 | $30.57M 10-K · filed 2025-02-20 | ||
| 2022-09-30 | $7.64M 10-Q · filed 2023-11-02 | $15.28M derived: sum of 2 quarters · filed 2023-11-02 | $22.93M 10-Q · filed 2023-11-02 | $30.57M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | $7.64M 10-Q · filed 2023-08-03 | $15.28M 10-Q · filed 2023-08-03 | $22.93M derived: sum of 3 quarters · filed 2024-02-22 | $30.57M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-03-31 | $7.64M 10-Q · filed 2023-05-04 | $15.28M derived: sum of 2 quarters · filed 2024-02-22 | $22.93M derived: sum of 3 quarters · filed 2024-02-22 | $30.57M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2021-12-31 | $7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $15.28M derived: sum of 2 quarters · filed 2024-02-22 | $22.93M derived: sum of 3 quarters · filed 2024-02-22 | $29.31M 10-K · filed 2024-02-22 | ||
| 2021-09-30 | $7.64M 10-Q · filed 2022-11-03 | $15.29M derived: sum of 2 quarters · filed 2022-11-03 | $21.67M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $7.64M 10-Q · filed 2022-08-04 | $14.02M 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $6.38M 10-Q · filed 2022-05-05 | |||||
| 2020-09-30 | $7.71M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $4.35M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |